Thirty two faculty members at the University of California San Diego are among the world’s most influential researchers in their fields, based on their publications over the past decade.
Using a database of multiple myeloma patient samples and information, researchers at University of California San Diego School of Medicine found that high ADAR1 levels correlate with reduced survival rates. They also determined that blocking the enzyme reduces multiple myeloma regeneration in experimental models derived from patient cancer cells.
A new small-molecule drug can restore brain function and memory in a mouse model of Alzheimer’s disease. The molecule, called anle138b, works by stopping toxic ion flow in the brain that is known to trigger nerve cell death. Scientists envision that this drug could be used to treat Alzheimer’s and other neurodegenerative diseases such as Parkinson’s and ALS.
Two full-time University of California San Diego faculty members — Don Cleveland, who studies fundamental cellular mechanisms in the search for new treatments for diseases like amyotrophic lateral sclerosis (ALS), and James McKernan, a mathematician who investigates algebraic geometry and multivariate polynomials — are recipients of the 2018 Breakthrough Prize, along with Joanne Chory, a plant biologist at Salk Institute for Biological Studies and adjunct professor in the Division of Biological Sciences at UC San Diego.
The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine (CIRM) unanimously approved yesterday two grants worth a total of almost $8 million to University of California San Diego School of Medicine researchers investigating novel stem cell-based treatments for acute myeloid leukemia or AML.
Glioblastoma, the most common and aggressive form of brain cancer, typically fails to respond to treatment or rapidly becomes drug resistant. In a paper published online in the journal Cancer Cell on November 30, University of California San Diego School of Medicine researchers identified a strategy that pinpoints a genetically distinct subpopulation of patients with glioblastoma that is particularly sensitive to drugs like cilengitide that target a cell adhesion receptor known as integrin αvβ3.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
